NeuroPace (NPCE) Net Cash Flow Growth (3y) (2023 - 2026)
Powered by 
Analysis
NeuroPace (NPCE) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -9.45% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -16.59% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -0.80% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 60.16% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -85.83% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 43.26% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 1.60% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -26.30% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 269.22% |
| 10 | NeuroPace | 493.15 Mn | 441.45 Mn | 18.91 Mn | -66.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -66.37% |
| Mar 31, 2026 | -284.21% |
| Dec 31, 2025 | 5.62% |
| Sep 30, 2025 | -300.42% |
| Jun 30, 2025 | -31.68% |
| Mar 31, 2025 | 46.74% |
| Dec 31, 2024 | 36.12% |
| Sep 30, 2024 | 36.63% |
| Jun 30, 2024 | -26.18% |
| Mar 31, 2024 | 26.12% |
| Dec 31, 2023 | 35.74% |
| Sep 30, 2023 | -61.70% |
| Jun 30, 2023 | 16.03% |
| Mar 31, 2023 | -72.61% |